The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Open accessAbstract
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic condition that has been termed coronavirus disease 2019 (COVID-19) and has reached pandemic proportions. As of 17 September 2020, more than 30 million confirmed SARS-CoV-2 infections have been reported in 204 different countries, claiming more than 1 million lives worldwide. Accumulating evidence suggests that SARS-CoV-2 infection can lead to a variety of clinical conditions, ranging from asymptomatic to life-threatening cases. In the early stages of the disease, most patients experience mild clinical symptoms, including a high fever and dry cough. However, 20% of patients rapidly progress to severe illness characterized by atypical interstitial bilateral pneumonia, acute respiratory distress syndrome and multiorgan dysfunction. Almost 10% of these critically ill patients subsequently die. Insights into the pathogenic mechanisms underlying SARS-CoV-2 infection and COVID-19 progression are emerging and highlight the critical role of the immunological hyper-response — characterized by widespread endothelial damage, complement-induced blood clotting and systemic microangiopathy — in disease exacerbation. These insights may aid the identification of new or existing therapeutic interventions to limit the progression of early disease and treat severe cases. This Review describes our current understanding of the pathogenic mechanisms involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the progression of coronavirus disease 2019 (COVID-19), focusing on the immunological hyper-response and the induction of widespread endothelial damage, complement-associated blood clotting and systemic microangiopathy, as well as the effects of these processes on the kidney. The authors also discuss therapeutic interventions that currently hold most promise. Although most patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience mild to moderate symptoms that resolve after 6–10 days, almost 20% of patients develop severe illness characterized by atypical interstitial bilateral pneumonia and acute respiratory distress syndrome, with a high fatality rate. Accumulating evidence suggests that an unbalanced and unrestrained innate immune response, which comes at the expense of effective adaptive immunity, underpins the progression of coronavirus disease 2019 (COVID-19). In severe cases of COVID-19, massive endothelial dysfunction, widespread coagulopathy and complement-induced thrombosis can lead to the development of systemic microangiopathy and thromboembolism; these complications can be life-threatening and ultimately lead to multi-organ failure. The kidney is one of the main targets of COVID-19 complications, and abnormal kidney function is associated with a significantly increased risk of death in severely ill patients. Most repurposed anti-viral drugs have failed to improve clinical outcomes in COVID-19; by contrast, therapeutic interventions that target the host response, including the hyper-immune response, complement activation and systemic thrombosis, seem to be more promising approaches to the treatment of severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–257 of 257
Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F., Cheng, F., Liu, Y., Zhou, T., Deng, B., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12880 · Cited by 225
The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike
Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., Xin, S., Cao, P., & Lu, J. (2020) · iScience · doi:10.1016/j.isci.2020.101400 · Cited by 224
The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
McKechnie, J. L., & Blish, C. A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.009 · Cited by 222
COVID-19 in kidney transplant recipients
Gandolfini, I., Delsante, M., Fiaccadori, E., Zaza, G., Manenti, L., Degli Antoni, A., Peruzzi, L., Riella, L. V., Cravedi, P., & Maggiore, U. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15891 · Cited by 211
The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike
Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., Xin, S., Cao, P., & Lu, J. (2020) · iScience · doi:10.1016/j.isci.2020.101160 · Cited by 211
Advances in understanding the pathogenesis of HLH
Usmani, G. N., Woda, B. A., & Newburger, P. E. (2013) · British Journal of Haematology · doi:10.1111/bjh.12293 · Cited by 202
Jiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0063-8 · Cited by 195
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.464 · Cited by 192
MAVS Coordination of Antiviral Innate Immunity
Vazquez, C., & Horner, S. M. (2015) · Journal of Virology · doi:10.1128/jvi.01918-14 · Cited by 187
(2015) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2014.12.001 · Cited by 186
Distinct phenotypes require distinct respiratory management strategies in severe COVID-19
Robba, C., Battaglini, D., Ball, L., Patroniti, N., Loconte, M., Brunetti, I., Vena, A., Giacobbe, D. R., Bassetti, M., Rocco, P. R. M., et al. (2020) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2020.103455 · Cited by 186
Carissimo, G., Xu, W., Kwok, I., Abdad, M. Y., Chan, Y.-H., Fong, S.-W., Puan, K. J., Lee, C. Y.-P., Yeo, N. K.-W., Amrun, S. N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19080-6 · Cited by 186
Self-citationCOVID-19 in Hemodialysis Patients: A Report of 5 Cases
Wang, R., Liao, C., He, H., Hu, C., Wei, Z., Hong, Z., Zhang, C., Liao, M., & Shui, H. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.03.009 · Cited by 174
Liu, Y., Pan, Y., Hu, Z., Wu, M., Wang, C., Feng, Z., Mao, C., Tan, Y., Liu, Y., Chen, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa630 · Cited by 173
COVID-19 vaccine design: the Janus face of immune enhancement
Hotez, P. J., Corry, D. B., & Bottazzi, M. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0323-4 · Cited by 168
Amrun, S. N., Lee, C. Y., Lee, B. T. K., Fong, S., Young, B. E., Chee, R. S., Yeo, N. K., Torres‐Ruesta, A., Carissimo, G., Poh, C. M., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102911 · Cited by 150
Self-citationCOVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle
Durvasula, R. V., Wellington, T., McNamara, E. A., & Watnick, S. G. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.04.001 · Cited by 145
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
Chung, M. K., Karnik, S. S., Saef, J., Bergmann, C. C., Barnard, J., Lederman, M. M., Tilton, J. C., Cheng, F., Harding, C. V., Young, J. B., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102907 · Cited by 143
COVID-19, microangiopathy, hemostatic activation, and complement
Song, W., & FitzGerald, G. A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140183 · Cited by 142
COVACTA trial raises questions about tocilizumab's benefit in COVID-19
Furlow, B. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30313-1 · Cited by 133
A hypothesized role for dysregulated bradykinin signaling in COVID‐19 respiratory complications
Roche, J. A., & Roche, R. (2020) · The FASEB Journal · doi:10.1096/fj.202000967 · Cited by 127
Kumar, V. C. S., Mukherjee, S., Harne, P. S., Subedi, A., Ganapathy, M. K., Patthipati, V. S., & Sapkota, B. H. (2020) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2020-000417 · Cited by 125
Ansarin, K., Tolouian, R., Ardalan, M., Taghizadieh, A., Varshochi, M., Teimouri, S., Vaezi, T., Valizadeh, H., Saleh, P., Safiri, S., et al. (2020) · Bioimpacts · doi:10.34172/bi.2020.27 · Cited by 124
Ali, H., Daoud, A., Mohamed, M., Salim, S. A., Yessayan, L., Baharani, J., Murtaza, A., Rao, V., & Soliman, K. (2020) · Renal Failure · doi:10.1080/0886022x.2020.1756323 · Cited by 122
Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection
Bermejo-Martín, J. F., Almansa, R., Menéndez, R., Méndez, R., Kelvin, D. J., & Torres, A. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.029 · Cited by 120
Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls
Ponticelli, C. E., & Locatelli, F. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12991117 · Cited by 110
Inside the lungs of COVID-19 disease
Aguiar, D., Lobrinus, J. A., Schibler, M., Fracasso, T., & Lardi, C. (2020) · International Journal of Legal Medicine · doi:10.1007/s00414-020-02318-9 · Cited by 107
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients
Bellesi, S., Metafuni, E., Hohaus, S., Maiolo, E., Marchionni, F., D’Innocenzo, S., Sorda, M. L., Ferraironi, M., Ramundo, F., Fantoni, M., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17034 · Cited by 106
Bermejo-Martín, J. F., Cillóniz, C., Méndez, R., Almansa, R., Gabarrús, A., Ceccato, A., Torres, A., Menéndez, R., & for the NEUMONAC group (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.023 · Cited by 103
O’Brien, K., Morrison, T. E., Dundore, D. Y., Heise, M. T., & Schultz‐Cherry, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017377 · Cited by 99
Intraoperative High-Dose Dexamethasone and Severe AKI after Cardiac Surgery
Jacob, K. A., Leaf, D. E., Dieleman, J. M., van Dijk, D., Nierich, A. P., Rosseel, P. M. J., van der Maaten, J. M., Hofland, J., Diephuis, J. C., de Lange, F., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080840 · Cited by 93
Page, A., Bravo, A., Suárez-Cabrera, C., Sánchez-Baltasar, R., Oteo, M., Morcillo, M. Á., Casanova, M. L., Segovia, J. C., Navarro, M., & Ramírez, Á. (2020) · International Journal of Oral Science · doi:10.1038/s41368-019-0067-9 · Cited by 92
Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen
Pernazza, A., Mancini, M., Rullo, E., Bassi, M., Giacomo, T. D., Rocca, C. D., & d’Amati, G. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02829-1 · Cited by 92
Stavrou, E. X., Fang, C., Merkulova, A. A., Alhalabi, O., Grobe, N., Antoniak, S., Mackman, N., & Schmaier, A. H. (2014) · Blood · doi:10.1182/blood-2014-01-550285 · Cited by 90
From lab to bedside: emerging clinical applications of thymosin α1
Goldstein, A. L., & Goldstein, A. L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902911412 · Cited by 89
A missing link between SARS‐CoV‐2 and the eye?: ACE2 expression on the ocular surface
Grajewski, R. S., Rokohl, A. C., Becker, M., Dewald, F., Lehmann, C., Fätkenheuer, G., Cursiefen, C., Klein, F., & Heindl, L. M. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26136 · Cited by 89
New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection
Patel, A. M., Charani, E., Ariyanayagam, D., Abdulaal, A., Denny, S., Mughal, N., & Moore, L. S. P. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.026 · Cited by 88
Aveolar Macrophage Activation and Cytokine Storm in the Pathogenesis of Severe COVID-19Preprint
Wang, C., Xie, J., Zhao, L., Fei, X., Zhang, H., Tan, Y., Zhou, L., Liu, Z., Ren, Y., Yuan, L., et al. (2020) · doi:10.21203/rs.3.rs-19346/v1 · Cited by 88
Fang, C., Stavrou, E. X., Schmaier, A. A., Grobe, N., Morris, M., Chen, A., Nieman, M. T., Adams, G. N., Larusch, G. A., Zhou, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-09-459156 · Cited by 84
Tan, L., Kang, X., Ji, X., Li, G., Wang, Q. M., Li, Y., Wang, Q., & Miao, H. (2020) · Med · doi:10.1016/j.medj.2020.05.002 · Cited by 82
Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury
Lim, J., Park, S.-H., Jeon, Y., Cho, J., Jung, H., Choi, J., Kim, C., Lee, Y.-H., Seo, H., Lee, J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061718 · Cited by 74
Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
van de Veerdonk, F. L., Kouijzer, I. J. E., de Nooijer, A. H., van der Hoeven, H. G., Maas, C., Netea, M. G., & Brüggemann, R. J. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.17708 · Cited by 65
Magoon, S., Bichu, P., Malhotra, V., Alhashimi, F., Hu, Y., Khanna, S., & Berhanu, K. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.05.004 · Cited by 64
COVID ‐19 of dialysis patients in Japan: Current status and guidance on preventive measures
The Japanese Society for Dialysis Therapy, The Japanese Society of Nephrology, Kikuchi, K., Nangaku, M., Ryuzaki, M., Yamakawa, T., Hanafusa, N., Sakai, K., Kanno, Y., Ando, R., et al. (2020) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13531 · Cited by 64
Caution in Identifying Coronaviruses by Electron Microscopy
Miller, S. E., & Goldsmith, C. S. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050755 · Cited by 58
Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2
Wang, Y.-T., Landeras-Bueno, S., Hsieh, L.-E., Terada, Y., Kim, K., Ley, K. F., Shresta, S., Saphire, E. O., & Regla-Nava, J. Á. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.05.012 · Cited by 51
Porfidia, A., & Pola, R. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02125-4 · Cited by 48
The compelling arguments for the need of microvascular investigation in COVID-19 critical patients
Martini, R. (2020) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-200895 · Cited by 46
Begum, J., Mir, N. A., Dev, K., Buyamayum, B., Wani, M. Y., & Raza, M. (2020) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13804 · Cited by 46
Deciphering and predicting CD4+ T cell immunodominance of influenza virus hemagglutinin
Cassotta, A., Paparoditis, P., Geiger, R., Mettu, R. R., Landry, S. J., Donati, A., Benevento, M., Foglierini, M., Lewis, D. J. M., Lanzavecchia, A., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200206 · Cited by 37
C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy
Williams, A. L., Gullipalli, D., Ueda, Y., Sato, S., Zhou, L., Miwa, T., Tung, K. S. K., & Song, W. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.018 · Cited by 32
Lee, K., Rhim, J. W., & Kang, J.-H. (2020) · Korean Journal of Pediatrics · doi:10.3345/cep.2020.00290 · Cited by 25
Menéndez, R., Méndez, R., Almansa, R., Ortega, A., Alonso, R., Suescún, M., Ferrando, A. D. G., Feced, L., & Bermejo-Martín, J. F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091404 · Cited by 21
Schmaier, A. H. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00061 · Cited by 18
(2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.4346 · Cited by 16
Shen, Y., Radhakrishnan, M. L., & Tidor, B. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24730 · Cited by 10
Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?
Noris, M., & Remuzzi, G. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.038 · Cited by 9
Self-citation
Cited by
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
The immunology and immunopathology of COVID-19
Merad, M., Blish, C. A., Sallusto, F., & Iwasaki, A. (2022) · Science · doi:10.1126/science.abm8108 · Cited by 751
COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far
Khan, M., Adil, S. F., Alkhathlan, H. Z., Tahir, M. N., Saif, S., Khan, M., & Khan, S. T. (2020) · Molecules · doi:10.3390/molecules26010039 · Cited by 584
Pretorius, E., Vlok, M., Venter, C., Bezuidenhout, J. A., Laubscher, G. J., Steenkamp, J., & Kell, D. B. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01359-7 · Cited by 518
Pathophysiology of COVID-19-associated acute kidney injury
Legrand, M., Bell, S., Forni, L., Joannidis, M., Koyner, J. L., Liu, K., & Cantaluppi, V. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00452-0 · Cited by 500
Metadata
- Authors
- Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G.
- Venue
- Nature Reviews Nephrology
- Published
- 2020-10-19
- Volume
- 17
- Issue
- 1
- Pages
- 46-64
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W3093214735
- Cited by
- 607
- References
- 257
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.